Findings showed the difference in mean change in BCVA at week 12 between ONS-5010 and ranibizumab was -1.009 letters. Topline data were announced from a phase 3 trial demonstrating ONS-5010 ...

When approved, ONS-5010/LYTENAVA™ will be the first and only FDA-approved ophthalmic formulation of bevacizumab supported by standardized manufacturing, FDA-approved labeling, and robust ...

Martínez-Castellanos and colleagues evaluated ocular function, neurodevelopment, and growth in infants treated with intravitreal bevacizumab injections for retinopathy of prematurity (ROP) during a ...

Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective from the Retina World Congress here, Terry Dagnon, ...

The FDR outcome directs FDA divisions to finalize labeling with the sponsor, reversing the prior CRL trajectory and ...

Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg, bevacizumab gamma) for the treatment of ...

September 26, 2006 — The US Food and Drug Administration (FDA) and Genentech, Inc, have notified healthcare professionals regarding safety labeling revisions for bevacizumab injection (Avastin) that ...

Mesothelioma in the United States: A Surveillance, Epidemiology and End Results (SEER)-Medicare investigation of treatment patterns and survival. This is an ASCO Meeting Abstract from the 2015 ASCO ...

Nicholas G. Anderson, MD, leads a discussion on how the first ophthalmic formulation of bevacizumab may impact the wet AMD treatment paradigm. Jim Kenney, RPh, MBA: We don’t always get extrapolation ...